Key guidelines and recommendations for the treatment of CSU.

The links below will take you to the Wiley Online Library, a non-Novartis website. 
 

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Zuberbier T et al. Allergy 2018;73(7):1393–1414.

Click to view


Guidelines for the evaluation and management of urticaria in adults and children.
Grattan CE, Humphreys F, on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Br J Dermatol 2007;157(6):1116–1123.

Click to view


BSACI guideline for the management of chronic urticaria and angioedema.
Powell RJ et al. Clin Exp Allergy 2015;45(3):547–565.

Click to view

 

 

BSACI, British Society for Allergy & Clinical Immunology; CSU, chronic spontaneous urticaria; EAACI, European Academy of Allergy and Clinical Immunology; EDF, European Dermatology Forum; GA2LEN, Global Allergy and Asthma European Network; WAO, World Allergy Organization.

 

XSU20-C016 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]